Fundz

Exai Bio Appoints Dave Daly as Chief Executive Officer

PRIVATEJul 24, 2024

Position

Chief Executive Officer

Company

Exai Bio

Dave Daly
daved@exai.bio
Palo AltoBiotechnologySoftwareScience And Engineering

Description

Exai Bio announced the appointment of Dave Daly as Chief Executive Officer. With over 30 years of experience in cancer diagnostics and executive leadership, Daly is poised to lead Exai’s accelerated product development and partnering strategy. Exai’s liquid biopsy platform uses RNA sequencing to identify a novel category of cancer-associated, small non-coding RNAs, termed oncRNAs.

Quick answer

Exai Bio Appoints Dave Daly as Chief Executive Officer (July 24, 2024). Exai Bio is based in Palo Alto, California, United States.

Who is the new Chief Executive Officer at Exai Bio?
Exai Bio named Dave Daly Chief Executive Officer, announced July 24, 2024.
What did Exai Bio announce on July 24, 2024?
Exai Bio announced the appointment of Dave Daly as Chief Executive Officer. With over 30 years of experience in cancer diagnostics and executive leadership, Daly is poised to lead Exai’s accelerated product development and partnering strategy.
What does Exai Bio do?
Exai Bio is a next-generation liquid biopsy company.
Where is Exai Bio based?
Exai Bio is based in Palo Alto, California, United States.
Which similar companies made leadership changes around the same time?
Atavistik Bio (August 12, 2024), Terremoto Biosciences (July 25, 2024), MasterControl (July 25, 2024) and Haya Therapeutics (July 18, 2024) also announced leadership changes within 45 days of Exai Bio.

Source: Fundz verified event record.

Other recent leadership changes in Science And Engineering and Biotechnology

Executive moves at companies in the same sectors within 45 days, from Fundz verified event records.

Who to call at Exai Bio, and when

A new leader at Exai Bio brings new priorities and often new vendors. The first weeks are when they listen.

  • An alert the day Exai Bio raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Exai Bio, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Exai Bio. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Exai Bio

Location

3350 W. BAYSHORE ROAD

Palo Alto, California, United States

About

Exai Bio is a next-generation liquid biopsy company. Our mission is to enable a world where cancer can be detected early, diagnosed accurately, treated in a personalized and targeted way, and ultimately cured. The company’s proprietary RNA and artificial intelligence-based liquid biopsy platform delivers clinical insights into cancer biology to enable the earliest, most accurate diagnosis of cancer. Exai Bio was founded with technology from the UCSF laboratory of Dr. Hani Goodarzi, and consists of veteran leaders in the RNA biology, liquid biopsy, and artificial intelligence/machine learning fields from both academia (UCSF, Stanford, MIT) and industry (Bluestar, CareDx, Evidation, Google, 23andMe, Deep Genomics). Exai Bio is supported by leading life sciences and tech investors including Section 32, Casdin Capital, and Two Sigma Ventures, who have been integral to advancing cancer diagnostics, and artificial intelligence and machine learning technologies.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Exai Bio changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

Dave
Likely contact at this company
••••••••@••••••••

See Dave's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Exai Bio's next move

Learn about Strategic plan

Exai Bio changed its leadership. Fundz had it the day it was filed, with the decision-maker at the company attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.